Denosumab is a monoclonal antibody directed against the receptor activator of nuclear factor kappa B ligand (RANKL). Denosumab has been shown to reduce the risk of skeletal-related events, including spinal cord compression, pathologic fracture and hypercalcemia of malignancy in patients with bone metastases. Hypocalcemia is a known side effect of denosumab, occurring in an estimated 8-14% of the patients. Here, we present an asymptomatic patient with stage-5 chronic kidney disease and severe hypocalcemia who had received denosumab 1 month earlier.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjms.2017.09.008 | DOI Listing |
Publication Analysis
Top Keywords
severe hypocalcemia
8
chronic kidney
8
kidney disease
8
denosumab-associated severe
4
hypocalcemia patient
4
patient chronic
4
denosumab
4
disease denosumab
4
denosumab monoclonal
4
monoclonal antibody
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!